Joseph P Lyssikatos

CHIEF SCIENTIFIC OFFICER · Enliven Therapeutics

Joseph P Lyssikatos (CHIEF SCIENTIFIC OFFICER) filed 4 Form 4 reports in the trailing twelve months (0 purchases, 4 sales), most often in Enliven Therapeutics, Inc. (ELVN). The largest single filing was $3.5M of ELVN (132,500 sh across 4 lots, as filed), executed Jan 8. Data as of Nov 8 2026.

Add to watchlist

Return, ttmiAverage return per filing, trailing twelve months

–

no purchases on file

Delay-adjustediThe same average, entered at disclosure dates

–

returns measure stock purchases only

Filings, ttm

0 buys · 4 sells

Median delay

–

measured on stock purchases

Volume, ttmiDollar value disclosed in the trailing twelve months

$4.2M

shares × price, as filed

Last traded

Feb 6

Filed Feb 10

Median ADV $83.7M across their filed names

Open performance→

Volume by month

Buys $0 Sells $5.9M

Shares × price, as filed · by filing month · past 24 months

Sectors filed on

Healthcare 4 filings

Sector per market data · by filing · past 12 months

Most traded names

ELVN

Enliven Therapeutics, Inc. ELVN · 0 buys · 11 sells 11 filings

Recent filings

ELVNSALE Enliven Therapeutics, Inc. View filing → $150K
7,500 sh × $20.03
Exec Jun 3 2025
Filed Jun 5 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $101K
5,030 sh × $20.07
Exec May 1 2025
Filed May 5 2025 · 5:30 PM ET ELVNSALE Enliven Therapeutics, Inc. View filing → $258K
12,500 sh × $20.61
Exec Mar 19 2025
Filed Mar 21 2025 · 5:30 PM ET